Special Issue

Aging, Inflammaging and Multimorbidity: What Is the Role of Endothelial Dysfunction?

Message from the Guest Editors

Endothelial dysfunction or loss of physiological properties such as vascular tone control, vascular permeability, hemostasis, neutrophil recruitment, and hormonal traffic, is a systemic alteration resulting in the induction of a pro-coagulant, anti-fibrinolytic state and low-chronic inflammation (inflammaging). With aging, the endothelial environment is perturbed by an increase in cytokines, chemokines, growth factors, proteases, and angiogenic factors that characterize a senescence-associated proinflammatory secretory phenotype, which results in a high susceptibility to chronic morbidity, disability, frailty, and death.

Guest Editors

Dr. Giuseppina Basta
Institute of Clinical Physiology, National Research Council (Cnr), via Moruzzi, 1, 56124 Pisa, Italy

Dr. Serena Del Turco
Institute of Clinical Physiology, National Research Council (Cnr), via Moruzzi, 1, 56124 Pisa, Italy

Deadline for manuscript submissions

closed (31 March 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/78415

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).